Here's a story about what happens when a big investor gets fed up. Shah Capital, which owns roughly 9% of Novavax Inc. (NVAX), said on Wednesday it plans to vote against the company's board nominees and executive pay packages at the upcoming 2026 annual meeting. The reason? A familiar tune in biotech: great science, not-so-great business.
The investor, in a letter filed Wednesday, didn't mince words. It argued that Novavax's leadership has failed to turn its promising vaccine platform into meaningful commercial success, leading to what Shah calls "prolonged shareholder value destruction." Translation: the stock hasn't done well, and they blame management.
The Commercial Struggle Is Real
The core of the complaint is about money, specifically the money Novavax isn't making from its flagship COVID-19 vaccine, Nuvaxovid. Shah Capital highlighted what it sees as a glaring disconnect: a vaccine with strong efficacy and safety data that captured only about 1% market share. The investor projects a paltry $22 million in revenue from it for 2025. For a company that was once a pandemic darling, that's a tough number to swallow.
Partnership Pains and Pipeline Delays
It's not just about the current product. Shah also expressed frustration with the pace of the company's high-profile partnership with Sanofi SA (SNY), particularly around launching a Phase 3 trial for a combined COVID-19 and influenza vaccine.
Novavax had shared promising Phase 3 data for that combo shot back in June 2025, showing robust immune responses. But Shah's point is simple: where's the progress? The investor notes this program targets a multibillion-dollar market but seems stuck in neutral "despite promising clinical data."
The broader question Shah poses is why Novavax's pipeline—which includes other combination vaccines—hasn't translated into stronger investor confidence, even with partnerships involving giants like Sanofi and Pfizer Inc (PFE). The company still faces elevated short interest, a sign that plenty of traders are betting the stock will go down.
Spending Too Much, Returning Too Little?
Then we get to the finances. Shah Capital criticized Novavax's cost discipline, arguing the company maintains an executive team and board that are too large for what is now largely a royalty-driven business. The hedge fund also flagged continued high spending on research and development (R&D) and sales, general, and administrative (SG&A) costs, despite what it says were prior investments exceeding $1 billion over recent years.
On capital allocation, Shah raised concerns about moves like a convertible bond extension in 2025 and what it described as the company holding onto too much cash while the stock languishes. The investor's suggestion? Retire outstanding debt and consider share buybacks to signal confidence and return value to shareholders.
The proposed fixes are structural. Shah wants governance changes, including a smaller board and a roughly 30% cut in senior management roles. It's also calling for a much sharper focus on profitability, targeting significantly lower operating expenses by 2027.
The Long-Term Bet
Shah Capital acknowledged Novavax's scientific capabilities—the underlying tech is still seen as valuable. But it pointed out the stark reality of the stock's sharp decline over the past three and five years. While the firm isn't launching a full-blown proxy fight (yet), it's urging other shareholders to join its dissent to push for strategic and governance reforms.
Perhaps most notably, Shah highlighted the idea of a "strategic long-term investor" taking a 10-20% ownership stake to, as the letter puts it, "reshape Novavax entirely." That's a clear signal that some investors believe the company's best path forward might require a major shakeup from the outside.
In the market's immediate reaction, Novavax shares were up 3.57% at $8.26 at the time of publication on Wednesday.
